Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980172 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1978663 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1979775 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL12598645 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1980306 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1982417 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1980305 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1982415 | 0.85 | USP2 (0.38) | USP2SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL1978328 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL1983350 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| CN-118239948-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117946107-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-117186097-A | Carboxamide derivative with RSK inhibition effect, pharmaceutical composition containing carboxamide derivative and application of carboxamide derivative | 上海科恩泰生物医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117186098-A | Carboxamide derivative with RSK inhibition effect, pharmaceutical composition containing carboxamide derivative and application of carboxamide derivative | 上海科恩泰生物医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023081857-A1 | CONDENSED PYRIDAZINE AMINE DERIVATIVES TREATING SCA3 | SKYHAWK THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| EP-1325008-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| WO-2002010169-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101747-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | USP2 3262/4885SMN1; SMN2 4423/4885NR1H2 1647/4885 |
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | USP2 3426/4885SMN1; SMN2 369/4885NR1H2 201/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | USP2 2342/4885SMN1; SMN2 1035/4885NR1H2 336/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | USP2 1060/4885SMN1; SMN2 491/4885NR1H2 403/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | USP2 1275/4885SMN1; SMN2 1242/4885NR1H2 630/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | USP2 451/4885SMN1; SMN2 2394/4885NR1H2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.